Overview

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
Phase:
Phase 2
Details
Lead Sponsor:
Theravance Biopharma
Theravance Biopharma R & D, Inc.